Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
38 hedge funds and large institutions have $26.8M invested in Aevi Genomic Medicine Inc in 2014 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 1 closing their positions.
1,500% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 1
175% more capital invested
Capital invested by funds: $9.77M → $26.8M (+$17.1M)
58% more funds holding
Funds holding: 24 → 38 (+14)
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$5.06M |
| 2 |
Jennison Associates
New York
|
+$4.85M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$4.2M |
| 4 |
PA
Perceptive Advisors
New York
|
+$2.27M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Legal & General Group
London,
United Kingdom
|
-$1.33M |
| 2 |
BGA
Belmont Global Advisors
Dallas,
Texas
|
-$708K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$47.5K |
| 4 |
LPL Financial
San Diego,
California
|
-$14.9K |
| 5 |
SIM
Spark Investment Management
New York
|
-$10.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $36K | -$2.47K | -500 | -7% |
|
|
LTFS
27
Ladenburg Thalmann Financial Services
Miami,
Florida
| $33K | +$32.6K | +6,597 | New |
|
28
Morgan Stanley
New York
| $27K | +$5.93K | +1,200 | +30% |
|
|
BA
29
BlackRock Advisors
Wilmington,
Delaware
| $19K | +$18.9K | +3,825 | New |
|
|
BIM
30
BlackRock Investment Management
Wilmington,
Delaware
| $14K | +$2.21K | +447 | +20% |
|
31
Citigroup
New York
| $9K | -$1.01K | -205 | -10% |
|
|
TWA
32
TCI Wealth Advisors
Tucson,
Arizona
| $5K | – | – | – |
|
33
Creative Planning
Overland Park,
Kansas
| $5K | +$4.64K | +940 | New |
|
|
BKA
34
Brick & Kyle Associates
Newtown,
Pennsylvania
| $5K | +$4.94K | +1,000 | New |
|
35
Simplex Trading
Chicago,
Illinois
| $1K | +$815 | +165 | New |
|
36
UBS Group
Zurich,
Switzerland
| $1K | +$988 | +200 | New |
|
|
TRCT
37
Tower Research Capital (TRC)
New York
| $1K | +$1.26K | +256 | New |
|
|
BRWA
38
B. Riley Wealth Advisors
Boca Raton,
Florida
| $10 | +$9.88K | +2,000 | New |
|
|
39
Legal & General Group
London,
United Kingdom
| – | -$1.33M | -255,193 | Closed |
|
GNMX Hedge Fund Activity: Q4 2014 in Review
38 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q4 2014, worth a combined $26.8M — up 175% from $9.77M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new GNMX positions and 1 closed out — a net gain of 15 holders — while 10 added to existing stakes and 7 trimmed.
The largest buyer was Broadfin Capital, opening a new position worth an estimated $5.06M. The largest seller was Legal & General Group, exiting entirely with an estimated $1.33M sold.
- 38 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q4 2014, up from 24 in Q3 2014.
- Funds reported $26.8M of Aevi Genomic Medicine Inc stock for Q4 2014, up 175% quarter-over-quarter.
- 16 funds opened new Aevi Genomic Medicine Inc positions in Q4 2014 and 1 closed out, a net change of +15 holders.
- The largest Aevi Genomic Medicine Inc buyer in Q4 2014 was Broadfin Capital, an estimated $5.06M added.
- The largest Aevi Genomic Medicine Inc seller in Q4 2014 was Legal & General Group, an estimated $1.33M sold.
Based on aggregated 13F filings for Q4 2014.